GW Pharmaceuticals PLC- (GWPH) Shares Sold by Advisors Asset Management Inc.

Advisors Asset Management Inc. trimmed its position in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 17.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,014 shares of the biopharmaceutical company’s stock after selling 1,934 shares during the quarter. Advisors Asset Management Inc.’s holdings in GW Pharmaceuticals PLC- were worth $1,258,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Flagship Harbor Advisors LLC bought a new position in shares of GW Pharmaceuticals PLC- during the 2nd quarter valued at $109,000. Envestnet Asset Management Inc. bought a new position in shares of GW Pharmaceuticals PLC- during the 2nd quarter valued at $119,000. Cowen Prime Services LLC lifted its holdings in shares of GW Pharmaceuticals PLC- by 708.0% during the 2nd quarter. Cowen Prime Services LLC now owns 1,010 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 885 shares during the period. NumerixS Investment Technologies Inc bought a new position in shares of GW Pharmaceuticals PLC- during the 2nd quarter valued at $166,000. Finally, BNP Paribas Arbitrage SA lifted its holdings in shares of GW Pharmaceuticals PLC- by 497.0% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 1,200 shares of the biopharmaceutical company’s stock valued at $167,000 after buying an additional 999 shares during the period. 69.94% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:GWPH opened at $147.25 on Friday. The company has a quick ratio of 8.21, a current ratio of 8.67 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $3.98 billion, a PE ratio of -21.19 and a beta of 2.61. GW Pharmaceuticals PLC- has a one year low of $105.12 and a one year high of $179.65.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) EPS for the quarter, topping the consensus estimate of ($2.40) by $1.14. The firm had revenue of $3.46 million during the quarter, compared to analyst estimates of $2.00 million. GW Pharmaceuticals PLC- had a negative return on equity of 47.65% and a negative net margin of 1,392.61%. Sell-side analysts expect that GW Pharmaceuticals PLC- will post -9.14 EPS for the current fiscal year.

Several equities analysts have recently weighed in on the company. ValuEngine raised GW Pharmaceuticals PLC- from a “buy” rating to a “strong-buy” rating in a report on Thursday. Cantor Fitzgerald set a $235.00 price target on GW Pharmaceuticals PLC- and gave the company a “buy” rating in a report on Thursday, July 12th. Stifel Nicolaus assumed coverage on GW Pharmaceuticals PLC- in a report on Tuesday, August 14th. They set a “buy” rating and a $181.00 price target on the stock. BidaskClub raised GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a report on Saturday, August 11th. Finally, Zacks Investment Research lowered GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research note on Friday, August 10th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $185.00.

GW Pharmaceuticals PLC- Profile

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Featured Article: Buyback

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply